Market Overview - The beverage and dairy sector experienced a decline of 0.54% on the trading day, with Junyao Health leading the drop [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Stock Performance - Notable gainers in the beverage and dairy sector included: - Weiweijia (600300) with a closing price of 3.47, up 2.97% [1] - New Dairy (002946) at 17.01, up 2.47% [1] - Yili (600887) at 27.36, up 0.66% with a transaction volume of 621,200 shares and a transaction value of 1.702 billion [1] - Major decliners included: - Junyao Health (605388) at 7.13, down 3.52% [2] - Happy Home (300997) at 16.62, down 3.26% [2] - Beiyinmei (002570) at 6.28, down 2.64% with a transaction value of 305 million [2] Capital Flow - The beverage and dairy sector saw a net inflow of 193 million from institutional investors, while retail investors experienced a net outflow of 39.39 million [2] - The capital flow for key stocks showed: - Yili (600887) had a net inflow of 285 million from institutional investors, but a net outflow of 172 million from retail investors [3] - Chengde Lululemon (000848) had a net inflow of 42.62 million from institutional investors, with a net outflow of 5.37 million from retail investors [3] - Miao Ke Lan Duo (600882) had a net inflow of 20.36 million from institutional investors, but a significant net outflow of 29.61 million from retail investors [3]

Core Insights - Junyao Health reported a revenue of approximately 329 million yuan for Q3 2025, representing a year-on-year decrease of 21.91% [1] - The company recorded a net loss attributable to shareholders of approximately 18.54 million yuan, which is a year-on-year increase in loss of 213.62% [1]

Group 1 - The core viewpoint of the article is that Junyao Health (605388.SH) reported a significant decline in revenue and net profit for the third quarter of 2025 [1] Group 2 - The company's operating revenue for the third quarter was 329 million yuan, representing a year-on-year decrease of 21.91% [1] - The net profit attributable to shareholders of the listed company was -9.83 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -13.20 million yuan [1]

证券代码：605388 证券简称：均瑶健康 公告编号：2025-058 湖北均瑶大健康饮品股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 10 月 29 日 (二)股东会召开的地点：上海市浦东新区康桥东路 2 弄 1 号楼大会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 314 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 407,692,620 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 69.5930 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东会由湖北均瑶大健康饮品股份有限公司（以下简称"公司"）董事 会召集，本次会议现场由董事长王均豪先生主持，采用现场与网络投 ...

北京 上海 深圳 杭州 广州 昆明 天津 成都 宁波 福州 西安 南京 南宁 济南 香港 巴黎 马德里 硅谷 BEIJING SHANGHAI SHENZHEN HANGZHOU GUANGZHOU KUNMING TIANJIN CHENGDU NINGBO FUZHOU XI'AN NANJING NANNING JINAN H O N G K O N G PARIS MADRID S I L I C O N V A L L E Y 上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai 200085 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 52433320 网址/Website: http://www.grandall.com.cn 国浩律师（上海）事务所 关于湖北均瑶大健康饮品股份有限公司 2025 年第三次临时股东会 法律意见书 致：湖北均瑶大健康饮品股份有限公司 根据《中华人民共和国公司法》（以下 ...

Group 1 - The core viewpoint of the news is that Junyao Health reported a decline in revenue and a net loss for the third quarter of 2025, indicating potential challenges for the company [1] - For the first three quarters of 2025, Junyao Health's revenue was approximately 1.095 billion yuan, representing a year-on-year decrease of 6.95% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 2.37 million yuan [1] Group 2 - As of the time of reporting, Junyao Health's market capitalization was 4.4 billion yuan [2]

Financial Performance - Total revenue for Q3 2025 was CNY 328,718,538.30, a decrease of 21.91% compared to the same period last year[4] - The total profit for the period was a loss of CNY 18,544,505.93, representing a decline of 213.62% year-on-year[4] - Net profit attributable to shareholders was a loss of CNY 9,834,901.33, down 167.09% from the previous year[4] - The basic earnings per share for the period was -CNY 0.0164, a decrease of 166.40% compared to the same period last year[5] - The company experienced a 365.11% decline in net profit after deducting non-recurring gains, totaling a loss of CNY 13,203,863.10 for the period[4] - Net profit attributable to shareholders for the current reporting period decreased to -167.09 million RMB, reflecting a significant drop in total profit[10] - Basic and diluted earnings per share for the current reporting period were both -166.3968 RMB, indicating a decline due to reduced total profit[10] - Net profit for the first three quarters of 2025 was a loss of CNY 11,371,197.00, compared to a profit of CNY 47,039,358.08 in 2024[28] - The company's operating profit for the first three quarters of 2025 was a loss of CNY 15,427,359.49, down from a profit of CNY 64,980,494.86 in the same period of 2024[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,017,573,820.66, a decrease of 12.79% from the end of the previous year[5] - The total liabilities decreased to CNY 319,056,799.83 in 2025 from CNY 548,716,746.59 in 2024, a reduction of 41.8%[24] - The total assets decreased to CNY 2,017,573,820.66 in 2025 from CNY 2,313,498,343.10 in 2024, a decline of 12.7%[24] - The company's equity attributable to shareholders decreased to CNY 1,715,649,397.36 in 2025 from CNY 1,772,911,604.62 in 2024, a decrease of 3.2%[24] Cash Flow - The cash flow from operating activities for the year-to-date was -CNY 87,189,611.93[4] - Cash inflow from sales of goods and services for the first three quarters of 2025 was $1,125,447,051.37, an increase of 5.76% compared to $1,064,200,690.63 in the same period of 2024[30] - Net cash flow from operating activities for the first three quarters of 2025 was -$87,189,611.93, compared to -$77,301,998.80 in 2024, indicating a decline in operational cash flow[30] - Total cash inflow from investment activities in the first three quarters of 2025 was $117,867,191.27, down from $172,694,409.60 in 2024, reflecting a decrease of 31.73%[31] - Net cash flow from investment activities improved to $48,856,444.18 in 2025, compared to -$106,178,718.47 in 2024, showing a significant recovery[31] - Cash inflow from financing activities totaled $48,153,848.80 in 2025, compared to $16,330,000.00 in 2024, marking a substantial increase of 194.56%[31] - The net cash flow from financing activities was -$52,088,707.44 in 2025, an improvement from -$87,380,733.01 in 2024[31] - The ending cash and cash equivalents balance for the first three quarters of 2025 was $135,448,848.48, down from $189,092,090.84 in 2024[31] Business Operations - The company reported a significant decline in probiotic beverage business revenue due to ongoing consumer demand pressures and market share loss in the dairy beverage sector[9] - The company's probiotic beverage revenue declined, leading to a year-on-year profit decrease of 213.62%[10] - The company is optimizing its revenue structure, with new product lines developing rapidly despite increased sales and marketing expenses[10] - The company’s overall operations showed resilience, with a commitment to technological innovation and quality improvement[14] - The company's probiotic food revenue reached 228 million RMB in the first three quarters of 2025, representing a year-on-year growth of 60.32%[15] - Online business saw a significant increase, with e-commerce sales growing by 120.84% compared to the same period last year[15] - The overseas channel business grew by 72.20% year-on-year, with products now covering over 80 countries and regions globally[15] - The probiotic business, as a core growth driver, achieved a revenue increase of 33.29% year-on-year[17] - The U.S. market showed strong performance, contributing nearly half of the overseas revenue, with significant order increases from key clients[19] - The company has successfully entered the pharmacy sector with its probiotic products, marking a new breakthrough in terminal coverage[21] Research and Development - The company increased R&D expenses, expanding its functional strain resource library to 50,000 strains, and launched a low-temperature probiotic beverage[10] - Research and development investment reached 28.41 million RMB in the first three quarters of 2025, marking a 20% increase compared to the previous year[17] - The company established a proprietary strain library of over 50,000 strains and created a "Six-Diamond" selection standard for quality benchmarks[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,338, with no preferred shareholders recovering voting rights[12] - The largest shareholder, Shanghai Junyao Group, holds 196,632,002 shares, representing 32.75% of the total shares[13] Accounting Standards - The company will not apply new accounting standards starting from 2025, as stated in the announcement[32]

证券代码：605388 证券简称：均瑶健康 公告编号：2025-059 湖北均瑶大健康饮品股份有限公司 2025 年前三季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号行业信息披露：第十二 号——酒制造》的相关规定，现将湖北均瑶大健康饮品股份有限公司（以下简称 "公司"）2025 年前三季度主要经营数据（未经审计）公告如下： 一、公司 2025 年前三季度主要经营情况： | 区域 | 2025 | 年1-9月主营业 务收入 | 2024 年 | 1-9 月主营业 务收入 | 变动比例 | | --- | --- | --- | --- | --- | --- | | 电商 | | 115,550,449.24 | | 52,323,513.26 | 120.84% | | 华东 | | 644,565,202.60 | | 779,495,163.25 | -17.31% | | 华中 | | 90,321,835.51 | | 133,941,308.1 ...

湖北均瑶大健康饮品股份有限公司 二〇二五年第三次临时股东会会议资料 湖北均瑶大健康饮品股份有限公司 二〇二五年第三次临时股东会 会议资料 | | | 湖北均瑶大健康饮品股份有限公司 二〇二五年第三次临时股东会会议资料 会议须知 湖北均瑶大健康饮品股份有限公司 二〇二五年第三次临时股东会会议资料 七、在股东会召开过程中，股东临时要求发言的应向股东会会 务组报名，并填写《股东意见征询单》，经股东会主持人许可后发 言。 为了维护全体股东的合法权益，确保股东会的正常秩序和议事 效率，保证股东会的顺利进行，根据中国证监会发布的《上市公司 股东会规则》、《湖北均瑶大健康饮品股份有限公司章程》（以下 简称"《公司章程》"）和《股东会议事规则》的规定，特制定本 须知，请出席股东会的全体人员遵照执行： 一、本公司根据《中华人民共和国公司法》、《中华人民共和 国证券法》、《上市公司股东会规则》、《公司章程》及《股东会 议事规则》的规定，认真做好召开股东会的各项工作。 二、本公司设立股东会会务组，具体负责股东会有关程序方面 的事宜。 三、本次股东会以现场会议形式召开。 四、为保证本次股东会的严肃性和正常秩序，切实维护股东的 合法权 ...

Core Insights - Junyao Health's stock price increased by 2.04% on October 21, reaching 7.49 CNY per share, with a market capitalization of 4.498 billion CNY [1] - The company has seen a year-to-date stock price increase of 20.57%, but a decline of 12.30% over the past 20 days [1] Financial Performance - For the first half of 2025, Junyao Health reported revenue of 766 million CNY, a year-on-year increase of 1.38%, while net profit attributable to shareholders decreased by 78.52% to 7.4661 million CNY [2] - Cumulative cash dividends since the company's A-share listing amount to 365 million CNY, with 132 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 58.20% to 42,700, while the average circulating shares per person decreased by 36.79% to 14,074 shares [2] - Tianhong Zhongzheng Food and Beverage ETF is among the top ten circulating shareholders, holding 831,800 shares as a new shareholder [3] Business Overview - Junyao Health, established on August 5, 1998, specializes in the research, production, and sales of room-temperature lactic acid bacteria beverages and other health drinks [1] - The company's revenue composition includes probiotic beverages (34.11%), commodity supply chain (34.07%), probiotic foods (21.98%), and other beverages and foods (9.55%) [1]